Repeated Remote Ischemic Conditioning Effect on Ankle-brachial Index in Diabetic Patients - A Randomized Control Trial

Shahvazian, Najmeh; Rafiee, Mansour; Rahmanian, Masoud; Razavi-ratki, Seyed Kazem; Farahzadi, Mohammad Hadi

Repeated Remote Ischemic Conditioning Effect on Ankle-brachial Index in Diabetic Patients - A Randomized Control Trial

Document Type : Original Article

Authors

¹ Cardiovascular Research Center, Shahid Sadoughi University of Medical Sciences and Health Services, Yazd, Iran

² Department of Endocrinology and Metabolism, Shahid Sadoughi University of Medical Sciences and Health Services, Yazd, Iran

³ Department of Nuclear Medicine, Shahid Sadoughi University of Medical Sciences and Health Services, Yazd, Iran

⁴ Department of Neuroscience, Faculty of Advanced Technologies in Medicine, Tehran University of Medical Sciences, Tehran, Iran

Abstract

Background: Remote ischemic preconditioning (RIPC) is a phenomenon where a short period of ischemia in one organ protects against further ischemia in the other organs. We hypothesized that RIPC occurring in diabetic patients with ankle brachial index (ABI) between 0.70 and 0.90 were included with peripheral arterial disease, would make the better coronary flow resulted in the increasing ABI. Materials and Methods: This randomized clinical trial study was done in the Afshar Cardiovascular Hospital in Yazd between 2013 and 2014. Sixty participants were randomly divided into two groups (intervention and control groups). The intervention group was undergoing RIPC, and the control group was tested without RIPC. RIPC was stimulated by giving three cycles of 5 min of ischemia followed by 5 min of reperfusion of both upper arms using a blood pressure cuff inflated to 200 mm Hg (n = 30). This was compared with no RIPC group which consisted of placing a deflated blood pressure cuff on the upper limbs (n = 30). Results: The mean of ABI level before intervention in the RIPC and control group group was 0.82 ± 0.055 and 0.83 ± 0.0603 (P = 0.347) respectively, with no significant difference. It was 0.86 ± 0.066 in the RIPC group compared the control 0.83 ± 0.0603 (P = 0.046). So levels of ABI were greater after intervention in the RIPC group. The mean of ABI level increase from 0.82 ± 0.05 to 0.86 ± 0.06 in RIPC group (P = 0.008). So the intervention group showed a significant increase in ABI. Conclusions: RIPC through using a simple, noninvasive technique, composing three cycles of 5 min-ischemia of both upper arms, showing a significant increase in ABI level in diabetic patients.

Keywords

References

1.	Hertzer NR, Beven EG, Young JR, O'Hara PJ, Ruschhaupt WF 3^rd, Graor RA, et al. Coronary artery disease in peripheral vascular patients. A classification of 1000 coronary angiograms and results of surgical management. Ann Surg 1984;199:223-33.
2.	Lloyd-Jones D, Adams R, Carnethon M, De Simone G, Ferguson TB, Flegal K, et al. Heart disease and stroke statistics-2009 update: A report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2009;119:e21-181.
3.	Bhatt DL, Peterson ED, Harrington RA, Ou FS, Cannon CP, Gibson CM, et al. Prior polyvascular disease: Risk factor for adverse ischaemic outcomes in acute coronary syndromes. Eur Heart J 2009;30:1195-202.
4.	Winsor T. Influence of arterial disease on the systolic blood pressure gradients of the extremity. Am J Med Sci 1950;220:117-26.
5.	Carter SA. Indirect systolic pressures and pulse waves in arterial occlusive diseases of the lower extremities. Circulation 1968;37:624-37.
6.	Yao ST, Hobbs JT, Irvine WT. Ankle systolic pressure measurements in arterial disease affecting the lower extremities. Br J Surg 1969;56:676-9.
7.	Criqui MH, Langer RD, Fronek A, Feigelson HS, Klauber MR, McCann TJ, et al. Mortality over a period of 10 years in patients with peripheral arterial disease. N Engl J Med 1992;326:381-6.
8.	Ankle Brachial Index Collaboration, Fowkes FG, Murray GD, Butcher I, Heald CL, Lee RJ, et al. Ankle brachial index combined with Framingham Risk Score to predict cardiovascular events and mortality: A meta-analysis. JAMA 2008;300:197-208.
9.	Ates E, Genç E, Erkasap N, Erkasap S, Akman S, Firat P, et al. Renal protection by brief liver ischemia in rats. Transplantation 2002;74:1247-51.
10.	Mallick IH, Yang W, Winslet MC, Seifalian AM. Ischaemic preconditioning improves microvascular perfusion and oxygenation following reperfusion injury of the intestine. Br J Surg 2005;92:1169-76.
11.	Tapuria N, Kumar Y, Habib MM, Abu Amara M, Seifalian AM, Davidson BR. Remote ischemic preconditioning: A novel protective method from ischemia reperfusion injury – A review. J Surg Res 2008;150:304-30.
12.	Murry CE, Jennings RB, Reimer KA. Preconditioning with ischemia: A delay of lethal cell injury in ischemic myocardium. Circulation 1986;74:1124-36.
13.	Przyklenk K, Bauer B, Ovize M, Kloner RA, Whittaker P. Regional ischemic 'preconditioning' protects remote virgin myocardium from subsequent sustained coronary occlusion. Circulation 1993;87:893-9.
14.	Przyklenk K. Efficacy of cardioprotective 'conditioning' strategies in aging and diabetic cohorts: The co-morbidity conundrum. Drugs Aging 2011;28:331-43.
15.	Przyklenk K, Darling CE, Dickson EW, Whittaker P. Cardioprotection 'outside the box' – the evolving paradigm of remote preconditioning. Basic Res Cardiol 2003;98:149-57.
16.	Przyklenk K, Frelinger AL 3^rd, Linden MD, Whittaker P, Li Y, Barnard MR, et al. Targeted inhibition of the serotonin 5HT2A receptor improves coronary patency in an in vivo model of recurrent thrombosis. J Thromb Haemost 2010;8:331-40.
17.	Przyklenk K, Heusch G. Late preconditioning against myocardial stunning. Does aspirin close the “second window” of endogenous cardioprotection? J Am Coll Cardiol 2003;41:1195-7.
18.	Przyklenk K, Li G, Simkhovich BZ, Kloner RA. Mechanisms of myocardial ischemic preconditioning are age related: PKC-epsilon does not play a requisite role in old rabbits. J Appl Physiol 2003;95:2563-9.
19.	Przyklenk K, Li G, Whittaker P. No loss in the in vivo efficacy of ischemic preconditioning in middle-aged and old rabbits. J Am Coll Cardiol 2001;38:1741-7.
20.	Przyklenk K, Maynard M, Darling CE, Whittaker P. Pretreatment with D-myo-inositol trisphosphate reduces infarct size in rabbit hearts: Role of inositol trisphosphate receptors and gap junctions in triggering protection. J Pharmacol Exp Ther 2005;314:1386-92.
21.	Przyklenk K, Maynard M, Darling CE, Whittaker P. Aging mouse hearts are refractory to infarct size reduction with post-conditioning. J Am Coll Cardiol 2008;51:1393-8.
22.	Przyklenk K, Maynard M, Greiner DL, Whittaker P. Cardioprotection with postconditioning: Loss of efficacy in murine models of type-2 and type-1 diabetes. Antioxid Redox Signal 2011;14:781-90.
23.	Przyklenk K, Maynard M, Whittaker P. First molecular evidence that inositol trisphosphate signaling contributes to infarct size reduction with preconditioning. Am J Physiol Heart Circ Physiol 2006;291:H2008-12.
24.	Przyklenk K, Maynard M, Whittaker P. Reduction of infarct size with D-myo-inositol trisphosphate: Role of PI3-kinase and mitochondrial K(ATP) channels. Am J Physiol Heart Circ Physiol 2006;290:H830-6.
25.	Przyklenk K, Undyala VV, Wider J, Sala-Mercado JA, Gottlieb RA, Mentzer RM Jr. Acute induction of autophagy as a novel strategy for cardioprotection: Getting to the heart of the matter. Autophagy 2011;7:432-3.
26.	Przyklenk K, Whittaker P.In vitro platelet responsiveness to adenosine-mediated “preconditioning” is age-dependent. J Thromb Thrombolysis 2005;19:5-10.
27.	Przyklenk K, Whittaker P. Cardioprotection with adenosine: 'A riddle wrapped in a mystery'. Br J Pharmacol 2005;145:699-700.
28.	Przyklenk K, Whittaker P. Adaptation of a photochemical method to initiate recurrent platelet-mediated thrombosis in small animals. Lasers Med Sci 2007;22:42-5.
29.	Przyklenk K, Whittaker P. Cardioprotection via adaptation to hypoxia: Expanding the timeline and targets? Basic Res Cardiol 2011;106:325-8.
30.	Kharbanda RK, Mortensen UM, White PA, Kristiansen SB, Schmidt MR, Hoschtitzky JA, et al. Transient limb ischemia induces remote ischemic preconditioning in vivo. Circulation 2002;106:2881-3.
31.	Rodrigo GC, Samani NJ. Ischemic preconditioning of the whole heart confers protection on subsequently isolated ventricular myocytes. Am J Physiol Heart Circ Physiol 2008;294:H524-31.
32.	Das M, Das DK. Molecular mechanism of preconditioning. IUBMB Life 2008;60:199-203.
33.	Saes GF, Zerati AE, Wolosker N, Ragazzo L, Rosoky RM, Ritti-Dias RM, et al. Remote ischemic preconditioning in patients with intermittent claudication. Clinics (Sao Paulo) 2013;68:495-9.
34.	Ates E, Genç E, Erkasap N, Erkasap S, Akman S, Firat P, et al. Renal protection by brief liver ischemia in rats. Transplantation 2002;74:1247-51.
35.	Harkin DW, Barros D'Sa AA, McCallion K, Hoper M, Campbell FC. Ischemic preconditioning before lower limb ischemia – reperfusion protects against acute lung injury. J Vasc Surg 2002;35:1264-73.
36.	Lai IR, Chang KJ, Chen CF, Tsai HW. Transient limb ischemia induces remote preconditioning in liver among rats: The protective role of heme oxygenase-1. Transplantation 2006;81:1311-7.
37.	Addison PD, Neligan PC, Ashrafpour H, Khan A, Zhong A, Moses M, et al. Noninvasive remote ischemic preconditioning for global protection of skeletal muscle against infarction. Am J Physiol Heart Circ Physiol 2003;285:H1435-43.
38.	Hausenloy DJ, Mwamure PK, Venugopal V, Harris J, Barnard M, Grundy E, et al. Effect of remote ischaemic preconditioning on myocardial injury in patients undergoing coronary artery bypass graft surgery: A randomised controlled trial. Lancet 2007;370:575-9.
39.	Hausenloy DJ, Yellon DM. Remote ischaemic preconditioning: Underlying mechanisms and clinical application. Cardiovasc Res 2008;79:377-86.
40.	Tapuria N, Kumar Y, Habib MM, Abu Amara M, Seifalian AM, Davidson BR. Remote ischemic preconditioning: A novel protective method from ischemia reperfusion injury – A review. J Surg Res 2008;150:304-30.
41.	Stewart KJ, Hiatt WR, Regensteiner JG, Hirsch AT. Exercise training for claudication. N Engl J Med 2002;347:1941-51.
42.	Cleveland JC Jr, Meldrum DR, Cain BS, Banerjee A, Harken AH. Oral sulfonylurea hypoglycemic agents prevent ischemic preconditioning in human myocardium. Two paradoxes revisited. Circulation 1997;96:29-32.
43.	Klepzig H, Kober G, Matter C, Luus H, Schneider H, Boedeker KH, et al. Sulfonylureas and ischaemic preconditioning; a double-blind, placebo-controlled evaluation of glimepiride and glibenclamide. Eur Heart J 1999;20:439-46.
44.	Clarke SJ, Khaliulin I, Das M, Parker JE, Heesom KJ, Halestrap AP. Inhibition of mitochondrial permeability transition pore opening by ischemic preconditioning is probably mediated by reduction of oxidative stress rather than mitochondrial protein phosphorylation. Circ Res 2008;102:1082-90.
45.	Weinbrenner C, Schulze F, Sárváry L, Strasser RH. Remote preconditioning by infrarenal aortic occlusion is operative via delta1-opioid receptors and free radicals in vivo in the rat heart. Cardiovasc Res 2004;61:591-9.
46.	Yellon DM, Downey JM. Preconditioning the myocardium: From cellular physiology to clinical cardiology. Physiol Rev 2003;83:1113-51.
47.	Blann AD, Belgore FM, McCollum CN, Silverman S, Lip PL, Lip GY. Vascular endothelial growth factor and its receptor, Flt-1, in the plasma of patients with coronary or peripheral atherosclerosis, or Type II diabetes. Clin Sci (Lond) 2002;102:187-94.
48.	Makin AJ, Chung NA, Silverman SH, Lip GY. Vascular endothelial growth factor and tissue factor in patients with established peripheral artery disease: A link between angiogenesis and thrombogenesis? Clin Sci (Lond) 2003;104:397-404.
49.	Findley CM, Mitchell RG, Duscha BD, Annex BH, Kontos CD. Plasma levels of soluble Tie2 and vascular endothelial growth factor distinguish critical limb ischemia from intermittent claudication in patients with peripheral arterial disease. J Am Coll Cardiol 2008;52:387-93.

Advanced Biomedical Research